Spots Global Cancer Trial Database for Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
Official Title: Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study
Study ID: NCT00903656
Conditions
Interventions
Study Description
Brief Summary: The aim of this study is to evaluate the potential of a Lapatinib plus Caelyx combination therapy as an effective and safe therapeutic regimen with a favourable cardiotoxicity profile, in the treatment of metastatic breast cancer following failure of prior trastuzumab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Uniklinik Salzburg, Salzburg, , Austria
Contact Details
Name: Alois Lang, Dr
Affiliation: LKH Feldkirch
Role: PRINCIPAL_INVESTIGATOR
Name: Rainhard Ziebermayr, Dr.
Affiliation: KH Elisabethinen Linz
Role: PRINCIPAL_INVESTIGATOR
Name: Richard Greil, Prof.
Affiliation: Uniklinik Salzburg
Role: PRINCIPAL_INVESTIGATOR
Name: Hellmut Samonigg, Prof.
Affiliation: Univ. Klinikum Graz
Role: PRINCIPAL_INVESTIGATOR
Name: Michael Fridrik, Doz.
Affiliation: AKH Linz
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
